Corvus Pharmaceuticals, INC Form 4 insider transactions
NASDAQ
Director Peter A. Thompson reports the acquisition of 15,000 stock options in Corvus Pharmaceuticals.
NASDAQ
Richard A. Miller, CEO of Corvus Pharmaceuticals, reported a gift of 302,016 common stock shares and maintains beneficial ownership of 577,634 shares directly and 1,188,103 shares indirectly through a trust.
NASDAQ
Form 4: Corvus Pharmaceuticals Director Peter Thompson Reports Acquisition of Pre-Funded and Common Warrants
Director Peter Thompson reports the acquisition of pre-funded and common warrants for Corvus Pharmaceuticals, indirectly held through OrbiMed Private Investments V, LP.
NASDAQ
Form 4: OrbiMed Advisors Acquires Warrants in Corvus Pharmaceuticals, Limits Exercise to Under 10% Ownership
OrbiMed Advisors LLC acquired pre-funded and common warrants in Corvus Pharmaceuticals on May 6, 2024, with exercise limitations to maintain ownership below 9.99%.
NASDAQ
William Benton Jones, SVP of Pharmaceutical Development at Corvus Pharmaceuticals, purchased 20,000 shares of common stock and acquired warrants to purchase 19,357 shares.
NASDAQ
Richard Miller, CEO of Corvus Pharmaceuticals, reports acquiring shares and warrants of the company's common stock.
NASDAQ
Jeffrey Arcara, Chief Business Officer of Corvus Pharmaceuticals, acquired stock options for 400,000 shares of common stock on February 28, 2024.